Avanos Medical Divests Hyaluronic Acid Product Line
Avanos Medical, Inc. (NYSE: AVNS) has announced a significant move by divesting its Hyaluronic Acid (HA) product line to Channel-Markers Medical, LLC. This transition reflects Avanos' ongoing commitment to transform and enhance its focus on key growth segments, such as Pain Management & Recovery and Specialty Nutrition Systems.
Strategic Alignment with Company Goals
The decision to divest this product line comes as part of a broader strategy aimed at streamlining Avanos’ offerings and aligning them with its core goals. The company is dedicated to providing targeted solutions that cater specifically to the needs of patients and healthcare providers alike.
Key Products Included in the Divestiture
The divested portfolio notably comprises the TriVisc and GenVisc 850 injections, which are recognized for their effectiveness in alleviating osteoarthritis pain in the knee. These HA therapeutic injections are essential for helping patients manage their OA symptoms, thereby improving their overall joint functionality and mobility.
Leadership Views on the Transaction
In light of the announcement, Dave Pacitti, CEO of Avanos, expressed optimism about this transaction. He stated, "This divestiture represents a meaningful step in advancing our transformation strategy and reinforcing our commitment to focused growth. We believe that aligning our product portfolio more closely with our strategic priorities will enable us to invest in areas where we see the highest potential for innovation and long-term value for our patients and shareholders."
About Channel-Markers Medical
Channel-Markers Medical specializes in joint health and minimally invasive pain management solutions. This acquisition is a strategic move for CMM, aiming to expand its footprint in musculoskeletal health and injectable pain therapies. David Toledo, a managing partner at CMM, remarked, "This acquisition aligns with our mission to deliver high-quality, clinically proven therapies that improve patient mobility and quality of life. We’re proud to integrate these trusted brands into our portfolio as we accelerate our growth in the pain therapy market."
Transition Support and Future Outlook
As part of the divestiture, Avanos will provide extensive transition support throughout the remainder of 2025, ensuring seamless service for customers, partners, and patients. This strategic decision not only paves the way for Avanos to concentrate on its core business but also fosters new growth opportunities for Channel-Markers Medical in the evolving healthcare market.
About Avanos Medical, Inc.
Avanos Medical, based in Alpharetta, Georgia, is a dedicated medical technology company that seeks to address pressing healthcare challenges. The company is focused on delivering solutions that enhance patient mobility and recovery from surgical procedures. Avanos is renowned for its wide-ranging product offerings addressing various healthcare needs including nutritional solutions and alternatives to opioid use.
Frequently Asked Questions
What products are included in the divestiture?
The divestiture includes TriVisc and GenVisc 850 injection products indicated for osteoarthritis pain treatment.
Why did Avanos decide to divest this product line?
The divestiture aligns with Avanos' strategy to focus on key segments and enhance growth in Pain Management and Recovery.
What will happen to existing customers of the HA product line?
Avanos will provide transition support until the end of 2025, ensuring uninterrupted service for customers, partners, and patients.
What is Channel-Markers Medical's specialization?
Channel-Markers Medical specializes in joint health, regenerative therapies, and minimally invasive pain management solutions.
How does this acquisition benefit Channel-Markers Medical?
This acquisition supports CMM's strategic goals in expanding its presence in musculoskeletal health and injectable pain therapies.
